Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Stoke Therapeutics, Inc. (STOK) had Return on Tangible Equity of -1.95% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$184.42M |
|
$-6.88M |
|
-- |
|
$184.42M |
|
$205.01M |
|
$-20.59M |
|
$13.71M |
|
$-6.88M |
|
$-6.88M |
|
$-6.88M |
|
$-6.88M |
|
$-6.88M |
|
$-6.88M |
|
$-20.59M |
|
$-19.95M |
|
59.22M |
|
59.22M |
|
$-0.12 |
|
$-0.12 |
|
| Balance Sheet Financials | |
$305.70M |
|
$3.15M |
|
$112.73M |
|
$418.43M |
|
$57.88M |
|
-- |
|
$8.10M |
|
$65.98M |
|
$352.46M |
|
$352.46M |
|
$352.46M |
|
58.92M |
|
| Cash Flow Statement Financials | |
$45.59M |
|
$-186.81M |
|
$97.39M |
|
$128.78M |
|
$84.94M |
|
$-43.84M |
|
$32.24M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.28 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-11.16% |
|
-11.16% |
|
-10.82% |
|
-3.73% |
|
-3.73% |
|
$44.91M |
|
-- |
|
-- |
|
-- |
|
0.44 |
|
-- |
|
23.33 |
|
15.65 |
|
-1.95% |
|
|
Return on Tangible Equity |
-1.95% |
-1.65% |
|
-1.95% |
|
$5.98 |
|
$0.76 |
|
$0.77 |
|